Polymorphs Form B, Form C, and amorphous of 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone, commonly known as cilostazol, have been identified. These polymorphs may be formed in pure form, in combination with each other, in combination with other polymorphs of cilostazol, or together with other pharmaceutical agents. Processes for preparing these polymorphs, and combinations of these polymorphs, as well as methods of use and unit dosages of these polymorphic forms, and their combinations, are described.

I polimorfi formano la B, forma C ed amorfo di 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone, conosciuto comunemente come cilostazol, sono stati identificati. Questi polimorfi possono essere formati nella forma pura, congiuntamente a vicenda, congiuntamente ad altri polimorfi del cilostazol, o insieme ad altri agenti farmaceutici. I procedimenti per la preparazione dei questi polimorfi e le combinazioni di questi polimorfi, così come i metodi di uso e di dosi unitarie di queste forme polimorfiche e delle loro combinazioni, sono descritti.

 
Web www.patentalert.com

< Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y

< Compositions and methods for treatment of sexual dysfunction

> Apoptosis inducing molecule II and methods of use

> Benzimidazole derivatives, processes for preparing them and their use as pharmaceutical compositions

~ 00073